Skip to main content

What You Must Know About Cystic Fibrosis Drug CTP-656

Acquiring CTP-656 from Concert Pharmaceuticals will only cost Vertex around $250 million.

Vertex Pharmaceuticals (VRTX) - Get Vertex Pharmaceuticals Incorporated Report is acquiring a longer-acting version of its Kalydeco cystic fibrosis drug from from Concert Pharmaceuticals  (CNCE) - Get Concert Pharmaceuticals, Inc. Report . Although both drugs are essentially the same, CTP-656 poses the possibility for a once-daily pill. 

READ THE FULL STORY HERE: Vertex Pharma Acquires Long-Acting Version of Cystic Fibrosis Drug From Concert Pharma

This article was written by a staff member of TheStreet.

Scroll to Continue

TheStreet Recommends